Pitolisant (excessive daytime sleepiness (EDS) with obstructive sleep apnoea (OSA) after previous therapy)

Subject:

• Active Substance: Pitolisant
• Name: Ozawade^®
• Therapeutic area: Obstructive sleep apnoea
• Pharmaceutical company: Bioprojet Deutschland GmbH

Time table:

• Start: 01.11.2021
• Final decision by G-BA: 21.04.2022

Final decision:

• No additional benefit proved